Tag: Clinical Trial
Breaking News
Global Biopharma R&D Boasts Increased Funding, Productivity and Product Launches in 2023, says IQVIA Institute Report
Clinical development productivity rose in 2023, primarily due to an improvement in the composite success rate, a function of phases successfully completed in the...
CIBC Innovation Banking Provides Growth Capital to InsightRX
SAN FRANCISCO–(BUSINESS WIRE)–CIBC Innovation Banking announced today that it has provided growth financing to InsightRX, a San Francisco-based software company leveraging quantitative pharmacology and...
Elon Musk Says First Neuralink Patient Can Move Computer Cursor With Mind
Neural interfaces could present an entirely new way for humans to connect with technology. Elon Musk says the first human user of his startup...
AI Is Streamlining Quality Control in Medicine Manufacturing
Quality control is a crucial but inefficient process in most manufacturing applications. Medicine producers face even more challenges than most. Their quality standards are...
IGC Pharma Reports Third Quarter Fiscal 2024 Results
POTOMAC, Md.–(BUSINESS WIRE)–#AD–IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024...
Karlsgate Revolutionizes Data Collaboration with New Remote Integration Capabilities
Unveiling a Groundbreaking Solution, Karlsgate Introduces a Full-Stack Approach to Privacy Protection
NEW YORK–(BUSINESS WIRE)–#data–Karlsgate is thrilled to announce the launch of KIE Integration, a...
Aerin Medical Announces Positive Two-year Outcomes from the VATRAC Trial of VivAer®
Third clinical trial demonstrating multi-year evidence of durable and significant benefit from VivAer treatment of nasal valve collapse
MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–#ENT—Aerin Medical Inc., a...
IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer’s Mouse Model
– The Company is targeting a Phase 1 trial in 2024 –
POTOMAC, Md.–(BUSINESS WIRE)–#AD–IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American:...
Aviceda Therapeutics Announces First Patient Dosed in Part 2 of the Phase 2/3 SIGLEC Clinical Trial Assessing AVD-104 for the Treatment of Geographic Atrophy
Part 2 of the Phase 2/3 SIGLEC clinical trial is designed and powered to serve as the first pivotal trial to support approval of...
WBA (Walgreens Boots Alliance) Digital Transformation Strategies Report 2023: Technology Focus and Initiatives, Partnerships, Investment & Acquisition Network Map, ICT Budget and Contracts –...
DUBLIN–(BUSINESS WIRE)–The “WBA – Digital Transformation Strategies” company profile has been added to ResearchAndMarkets.com’s offering.
Walgreens Boots Alliance Inc (Walgreens Boots Alliance) is a retail...
Trialbee and Massive Bio Join Forces to Improve Clinical Trial Access and Patient Recruitment for Oncology and Hematology
Aggregating channels with precision outreach to patients, family members, and oncologists/hematologists improves clinical research access for all
MALMO, Sweden & NEW YORK–(BUSINESS WIRE)–Trialbee, your global...
Tevogen Bio Appoints Globally Prominent Physicist Specializing in Space Biology, COVID-19, and AI Democratization, Afshin Beheshti, to Advisory Board
The appointment of Afshin Beheshti, PhD, contributes to the diversity of thought leadership within Tevogen Bio by way of his roles as Bioinformatician and...
Latest Intelligence
